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bjectives The aim of this study was to assess the 6-year clinical outcome after unrestricted use of
irolimus-eluting stents (SES) or paclitaxel-eluting stents (PES) as compared with bare-metal stents
BMS) in consecutive de novo patients undergoing percutaneous coronary intervention (PCI).
ackground SES and PES have been shown to signiﬁcantly decrease target vessel revascularization
TVR) rates compared with BMS in “real-world” registries. However, possible higher rates of very-late
tent thrombosis and a restenosis “catch-up” trend might jeopardize the beneﬁt.
ethods Three PCI cohorts, each with exclusive use of 1 stent type (BMS  450; SES  508; PES 
76), were systematically followed for the occurrence of major adverse cardiac events (MACE).
esults Very-late stent thrombosis was more common in SES and PES patients than BMS patients
2.4% vs. 0.9% vs. 0.4%, respectively; p  0.02); however, there were no signiﬁcant differences be-
ween the stent types for all-cause mortality and all-cause mortality/myocardial infarction at 6-year
ollow-up. Sixty-nine SES patients (Kaplan-Meier estimate 14%) and 72 PES patients (14%) had a TVR,
s compared with 79 BMS patients (18%; log-rank p  0.02), which maintained signiﬁcance after
djustment for (potential) confounders. Multivariate analysis showed that DES implantation is associ-
ted with lower incidence of TVR and MACE than BMS implantation (hazard ratio: 0.65, 95% conﬁ-
ence interval: 0.49 to 0.86; p  0.003; hazard ratio: 0.79, 95% conﬁdence interval: 0.65 to 0.97; p 
.02, respectively). Incidence of MACE was also lower in SES and PES patients (30% and 30%, respec-
ively) than in BMS patients (34%); however, signiﬁcance was borderline.
onclusions The unrestricted use of both DES resulted in a sustained advantage in decreasing TVR
nd, to a lesser extent, MACE compared with BMS at 6 years. The SES and PES are equally safe and
ffective in the treatment of coronary lesions. (J Am Coll Cardiol Intv 2010;3:1051–8) © 2010 by
he American College of Cardiology Foundation
rom the Thoraxcenter, Department of Cardiology, Erasmus Medical Center Rotterdam, Rotterdam, the Netherlands. Dr. Simsek
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1052n the last decade several randomized clinical trials and
egistries assessed the short- and long-term clinical outcome
f sirolimus-eluting stents (SES) and paclitaxel-eluting
tents (PES) (1–6). Although drug-eluting stents (DES)
ead to a decrease in angiographic restenosis and target
essel revascularization (TVR) rates compared with bare-
etal stents (BMS), DES caused novel safety concerns such
s possible higher very-late stent thrombosis rates (7,8). The
ccurrence of stent thrombosis is not merely a result of
remature discontinuation of dual antiplatelet therapy but
ather a multifactorial problem caused by several detrimental
eatures, including clinical, coronary lesion, and procedural
haracteristics (9–14). The higher likelihood of late stent
alapposition after DES implantation, which is associated
ith very-late stent thrombosis (1 year after stent implan-
ation), could jeopardize the very long-term clinical benefi-
ial value of DES. Also the observation of a possible clinical
TVR “catch-up” phenomenon
in the DES-population is of
concern (15–18).
The long-term clinical results
of the treatment of “all-comer”
percutaneous coronary interven-
tion (PCI) patients without us-
ing any exclusion criteria have
been described by our group in
the RESEARCH (Rapamycin-
Eluting Stent Evaluated at Rot-
terdam Cardiology Hospital) and
T-SEARCH (Taxus–Stent Evalu-
ated At Rotterdam Cardiology
Hospital) registries (19,20). Al-
though DES have shown supe-
rior short- and long-term clini-
cal outcome with regard to TVR
rates compared with BMS, it
remains unknown whether this
ffect is sustained. Therefore, the purpose of the present
eport is to investigate the safety and efficacy profile of the
nrestricted use of SES and PES versus BMS in de novo
atients undergoing PCI at 6-year follow-up.
ethods
atient population and study design. During specific time
eriods between October 2001 and September 2003, a total
f 1,534 consecutive de novo patients were treated with PCI
n 3 “real world” registries (Fig. 1). All patients remained in
heir first original enrolled cohort during the follow-up
eriod, and those receiving multiple stent types during the
nitial procedure were excluded from analysis. In total, 508
onsecutive patients underwent a PCI from April 2002 until
ctober 2002 in which only SES (Cypher, Cordis Corp.,
bbreviations
nd Acronyms
MS  bare-metal stent(s)
I  confidence interval
ES  drug-eluting stent(s)
R  hazard ratio
ACE  major adverse
ardiac events
I  myocardial infarction
CI  percutaneous
oronary intervention
ES  paclitaxel-eluting
tent(s)
ES  sirolimus-eluting
tent(s)
VR  target vessel
evascularizationohnson & Johnson, Warren, New Jersey) were implanted ms part of the RESEARCH registry (19). From February
003 until September 2003, 576 “all-comer” patients were
reated with the PES (TAXUS, Express2, or Liberté;
oston Scientific, Natick, Massachusetts) as the default
trategy for all PCI as part of the T-SEARCH registry (20).
hese patients were compared with 450 BMS patients
reated in the last 6-month period of the pre-SES era.
The RESEARCH and T-SEARCH registries have been
escribed previously and were conducted according to the
ynamic registry design described by Rothman et al. (21).
ll procedures were performed according to standard clin-
cal guidelines, and every patient was pre-treated with
spirin and 300 mg of clopidogrel. The post-PCI anti-
latelet regimen consisted of 80 mg aspirin lifelong and
75 mg clopidogrel for at least 1 month if BMS were used,
3 months for patients with SES, and 6 months for
atients with PES. Periprocedural glycoprotein IIb/IIIa
ntagonists were used at the discretion of the treating
nterventional cardiologist. All of the repeat coronary an-
iographies were clinically driven for the BMS group. Due
o specific subgroup analysis 18% of the PES patients and
6% of the SES patients had a scheduled repeat coronary
ngiography at 6 months, in which nonclinically driven
VR might have occurred. After 6 months, all coronary
ngiographies of the SES and PES patients were clinically
riven by physical symptoms or diagnostic findings sugges-
ive of myocardial ischemia. The study protocol was ap-
roved by the institutional ethics committee, and all pa-
ients provided written informed consent.
eﬁnitions and clinical end points. Procedural success was
efined as successful stent deployment and a residual ste-
osis 30% by visual analysis in the presence of Throm-
olysis in Myocardial Infarction flow grade 3 without the
ccurrence of MACE within 2 days after intervention.
Definite stent thrombosis was defined as angiographically
ocumented thrombus in or within 5 mm of the stent,
ccompanied by at least 1 of the following (as recommended
y the Academic Research Consortium criteria): 1) acute
ymptoms; 2) ischemic electrocardiographic changes; and
) typical rise and fall of cardiac markers. Stent thrombosis
as categorized into early (within 30 days after stent implan-
ation), late (within 30 days and 1 year after stent implanta-
ion), and very-late (after 1 year after stent implantation).
The primary end point was the occurrence of patient-
rientated MACE (defined as a composite of all-cause
ortality, any myocardial infarction [MI], and TVR).
fficacy end point included TVR, whereas safety end points
onsisted of stent thrombosis, all-cause mortality, and the
omposite of all-cause mortality/any MI. Myocardial infarc-
ion was diagnosed by recurrent typical clinical symptoms,
he development of ST-segment elevation or left bundle
ranch block on electrocardiography with a creatine kinase-
yocardial band rise of 3 the upper limit of normal and/or
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1053ositive troponin levels in the laboratory values. A TVR was
efined as a repeat PCI in the same vessel as the index
rocedure, in the presence of ischemic symptoms, or
ositive functional ischemia study on the target vessel
rea and a significant minimal luminal diameter stenosis
f at least 50%.
ollow-up. The municipal civil registries were contacted
early until December 2009 to document the clinical status
f treated patients. All living patients received a question-
aire, consisting of queries regarding repeat hospital stay
nd MACE. In case of a suspected event, the medical
ecords and coronary angiographies from our hospital or the
eferring institution were systematically reviewed by 2 inde-
endent experienced interventional cardiologists.
tatistical analysis. Continuous baseline variables were
ested with the analysis of variance test with post-hoc
orrection, and the chi-square test was used for the cate-
orical baseline variables. The estimated cumulative adverse
ardiac events for the end points (MACE, TVR, mortality,
nd mortality/MI) were generated with the Kaplan-Meier
ethod, and the differences among the 3 stent curves were
ested with the log-rank test.
A multivariate Cox proportional hazard regression model
95% confidence interval [CI] and p value 0.05 regarded
s significant) including all variables that had a p value0.5
n univariable analysis was used to adjust for baseline
haracteristics. Backward deletion of the least significant
ariables was performed until all variables had a p value of
.10 (these variables included age, hypercholesterolemia,
rior intervention, diabetes, multivessel disease, left main
isease, bypass graft stenting, type b2 lesion, number of
tents implanted, and total stented length). Patients lost to
ollow-up were considered at risk until the date of last
BMS = 450 pts SES = 508 pts
Apr 2002 -Oct 2002 Feb 2003
PES = 576 pts
RESEARCH T-SEARCH
-Sep 2003Oct 2001-Mar 2002
BMS Cohort
Figure 1. Chronological Order of the 3 Cohorts (n  1,534)
The 3 cohorts (bare-metal stent [BMS] cohort/RESEARCH [Rapamycin-Eluting
Stent Evaluated at Rotterdam Cardiology Hospital] and T-SEARCH [Taxus–
Stent Evaluated At Rotterdam Cardiology Hospital] registries). The com-
bined use of different types of stents in the same procedure resulted in
exclusion of the patient. If patients had multiple revascularization proce-
dures, they were only enrolled in the ﬁrst original cohort. PCI  percutane-
ous coronary intervention; PES  paclitaxel-eluting stent(s); SES 
sirolimus-eluting stent(s).ontact, at which point they were censored. All statistical wnalyses were performed with SPSS for Windows version 15
SPSS, Inc., Chicago, Illinois).
esults
opulation characteristics. Survival status was available for
8% of the patients. The baseline and procedural charac-
eristics of the BMS, SES, and PES groups are shown in
able 1. In summary, the population consisted mostly of
en (71%), and the mean age was 61 years ( 11.1 years).
here were no significant differences in baseline character-
stics among the 3 groups, except for BMS patients who had
ore prior PCIs (p  0.01) compared with SES and PES
atients. Significantly more patients presented with an acute
oronary syndrome in the PES group. Type C and bifurca-
ion lesions were more often treated in the SES and PES
roups (p  0.01). There were more stents with smaller
iameters implanted in the SES and PES patients with a
onger total stented length compared with BMS patients
p  0.01).
The usage of glycoprotein IIb/IIIa inhibitors was more
ommon in the BMS population compared with the SES
nd PES population (p  0.01). The duration of clopi-
ogrel usage after stent implantation increased over time,
eing shortest for the BMS group (mean of 1 month) and
ongest in the PES population (mean of 6 months).
-year outcome: safety end points. The cumulative inci-
ence and the associated adjusted multivariate hazard ratios
HRs) (BMS vs. SES, BMS vs. PES, SES vs. PES) of the
-year follow-up of the BMS, SES, and PES cohorts are
hown in Table 2 for each of the safety end points (i.e.,
tent thrombosis, all-cause mortality, and all-cause mor-
ality/any MI).
Although very-late stent thrombosis was more common in
ES patients than BMS patients (SES  2.4% vs. PES 
.9% vs. BMS  0.4%; [analysis of variance] p value  0.02;
Bonferroni-test] BMS vs. SES 0.02, BMS vs. PESNS,
ES vs. PES  NS), it did not influence the incidence of the
nd points all-cause mortality and the composite end point of
ll-cause mortality or MI at 6-year follow-up on multivariate
nalysis (Tables 2 and 3).
-year outcome: efﬁcacy end points. Univariate analysis
howed that there were no significant differences in MACE
nd TVR rates between SES and PES at 6 years (HR: 0.95,
5% CI: 0.85 to 1.06; HR: 1.02, 95% CI: 0.87 to 1.21,
espectively) and therefore we could analyze both SES and
ES together as a broader DES group (n  1,084). The
VR rates of PES patients were significantly lower com-
ared with BMS patients (HR: 0.84, 95% CI: 0.71 to 0.98)
nd borderline significant for SES patients (HR: 0.86, 95%
I: 0.73 to 1.01). DES significantly reduced TVR rates
HR: 0.72, 95% CI: 0.55 to 0.95); however, MACE rates
ere similar (HR: 0.91, 95% CI: 0.75 to 1.10).
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1054The multivariate Cox regression analysis showed that
ACE rates were lower in the DES group compared with
he BMS group (HR: 0.79, 95% CI: 0.65 to 0.97). This was
rimarily because significantly fewer TVR procedures were
Table 1. Baseline and Procedural Characteristics Str
BMS (n  45
Demographic characteristics
Age, yrs (SD) 60.8 (10.9
Male (%) 70.4
Cardiac history
Prior MI 39.7
Prior CABG 8.0
Prior PCI 18.0
Risk factors
Current smoking 34.0
Hypertension 37.6
Hypercholesterolemia 55.3
Diabetes 14.9
Insulin-dependent 4.0
Non–insulin-dependent 10.9
Family history 28.2
Clinical presentation
Stable angina 47.3
Unstable angina 34.7
Acute myocardial infarction 17.8
Cardiogenic shock 2.0
Disease severity
Multivessel disease 47.8
Bifurcation 7.8
Number of stents (SD) 1.8 (1.1)
Average stent diameter, mm 3.2
Total stent length, mm 30.1
Treated vessel
RCA 34.0
LAD 59.3
LCX 32.9
LM 2.2
Bypass graft 2.0
AHA lesion class
Type A 19.6
Type B1 31.8
Type B2 49.3
Type C 29.8
Success rate
Procedural success 97.3
Thrombocyte aggregation inhibitor
Clopidogrel duration, months (SD) 1.0 (0.1)
Glycoprotein IIb/IIIa inhibitor 33.3
Data are presented as percentages or mean (SD), unless otherwise in
AHA American Heart Association; BMS bare-metal stent(s); CA
artery; LCX left circumflex coronary artery; LM left main coronary a
PES paclitaxel-eluting stent(s); RCA right coronary artery; SES serformed in the DES group (HR: 0.65, 95% CI: 0.49 to a.86). The same findings were present for TVR when SES
nd PES were independently compared with BMS (HR:
.81, 95% CI: 0.68 to 0.96; and HR: 0.81, 95% CI: 0.68 to
.96, respectively) with lower Kaplan-Meier estimates (14%
According to Stent Type
SES (n  508) PES (n  576) p Value
61.1 (11.0) 61.7 (11.4) 0.3
67.9 73.6 0.4
29.9 34.5 0.01
9.3 6.1 0.4
18.7 18.2 0.8
30.7 29.0 0.3
41.3 41.8 0.2
55.5 62.2 1.0
17.7 18.4 0.3
5.9 5.2 0.2
11.8 13.4 0.7
32.5 40.6 0.2
44.3 44.8 0.6
37.2 27.1 0.01
18.1 28.1 0.01
1.8 3.6 0.1
54.1 56.1 0.1
15.7 16.0 0.01
2.2 (1.4) 2.2 (1.5) 0.01
2.8 3.0 0.01
38.8 42.9 0.01
38.6 37.8 0.1
58.7 55.4 0.9
31.7 33.3 0.7
3.0 4.3 0.6
3.3 3.3 0.2
21.9 7.3 0.2
30.7 25.0 0.8
48.6 54.3 0.8
42.5 47.2 0.01
97.2 97.4 0.9
4.2 (2.0) 6 (0.0) 0.01
19.3 27.6 0.01
.
oronary artery bypass graft; LAD left anterior descending coronary
Imyocardial infarction; PCI percutaneous coronary intervention;
-eluting stent(s).atified
0)
)
dicated
BG c
rtery; Mnd 18%; log-rank p  0.02, respectively) (Figs. 2 and 3),
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1055lthough significance was borderline for MACE (HR: 0.90,
5% CI: 0.80 to 1.01; and HR: 0.89, 95% CI: 0.79 to 1.00,
espectively). No significant differences were observed for
ACE and TVR rates between SES and PES.
iscussion
he 2-year follow-up of the T-SEARCH registry and the
-year follow-up of the RESEARCH registry have already
een published (3,22). Briefly, there were no significant
ifferences in MACE between PES and SES (18.9% vs.
5.4%, p  0.12) in the T-SEARCH registry at 2-year
ollow-up, but the incidence of MACE was higher in the
Table 2. Crude Event Rates and Multivariate Analysis Stratified According
n (%)
BMS (n  450) SES (n  508) PES (
Mortality
2-yr 28 (6.2%) 29 (5.7%) 43
6-yr 77 (17.1%) 83 (16.3%) 92
∆2–6 yrs 49 (10.9%) 54 (10.6%) 49
Mortality/MI
2-yr 53 (11.8%) 49 (9.6%) 67
6-yr 105 (23.3%) 111 (21.9%) 122
∆2–6 yrs 52 (11.5%) 62 (12.3%) 55
TVR
2-yr 63 (14.0%) 39 (7.7%) 52
6-yr 79 (17.6%) 69 (13.6%) 72
∆2–6 yrs 16 (3.6%) 30 (5.9%) 20
MACE
2-yr 99 (22.0%) 77 (15.2%) 106
6-yr 153 (34.0%) 151 (29.7%) 172
∆2–6 yrs 54 (12.0%) 74 (14.5%) 66
CI confidence interval; HR hazard ratio; MACEmajor adverse cardiac events; other abbreviat
Table 3. Incidence of ST in the 3 PCI Cohorts
n (%)
BMS
(n  450)
SES
(n  508)
Early ST 8 (1.8%) 2 (0.4%)
Acute ST 4 (0.9%) 1 (0.2%)
Subacute ST 4 (0.9%) 1 (0.2%)
Late ST 2 (0.4%) 2 (0.4%)
Very-late ST 2 (0.4%) 12 (2.4%)
Total ST 12 (2.7%) 16 (3.1%)
Stent thrombosis (ST) occurringwithin 30 days after stent implantation
(1 to 30 days). Late ST is defined as ST occurring between 30days and 1
as very-late ST.ANOVA analysis of variance; other abbreviations as in Tables 1 and 2.MS group compared with the SES group (28.7% vs.
3.0%, p  0.05) in the RESEARCH registry at 4-year
ollow-up. The main finding of the 6-year follow-up of the
ESEARCH and T-SEARCH registries is that DES
educed TVR by 35% and MACE by nearly 20% compared
ith BMS at 6-year follow-up in an unselected population.
lthough several clinical trials found contradictory results
or SES outperforming PES in terms of TVR rates, no
ignificant differences were found between SES and PES for
ll investigated end points at 6 years in our study (23–28).
he Kaplan-Meier curve illustrates that the TVR- and
ACE-graphic lines for both DES remain nearly parallel
o the BMS-graphic line after 1 year of follow-up, proving
ferent Stent Types at 6 Years
Multivariate HR (95% CI)
76) BMS vs. SES BMS vs. PES PES vs. SES
0.90 (0.69–1.18) 0.97 (0.75–1.26) 0.96 (0.75–1.23)
) 1.00 (0.85–1.18) 0.97 (0.82–1.15) 1.00 (0.86–1.17)
0.95 (0.84–1.09) 0.86 (0.56–1.33) 0.98 (0.80–1.12)
) 0.88 (0.72–1.08) 0.97 (0.79–1.18) 0.98 (0.81–1.18)
) 0.97 (0.84–1.11) 0.94 (0.81–1.08) 1.02 (0.89–1.17)
0.94 (0.83–1.06) 0.92 (0.60–1.40) 0.92 (0.76–1.12)
0.66 (0.54–0.82) 0.77 (0.63–0.93) 0.95 (0.77–1.18)
) 0.81 (0.68–0.96) 0.81 (0.68–0.96) 1.06 (0.89–1.26)
0.87 (0.71–1.07) 0.83 (0.42–1.64) 0.86 (0.64–1.15)
) 0.75 (0.64–0.88) 0.85 (0.74–0.99) 0.96 (0.82–1.11)
) 0.90 (0.80–1.01) 0.89 (0.79–1.00) 1.01 (0.90–1.14)
) 0.92 (0.82–1.04) 0.80 (0.54–1.18) 0.96 (0.80–1.14)
in Table 1.
ANOVA
p Value Bonferroni Test
PES
n  576)
7 (1.2%) 0.1 NS
1 (0.2%) 0.3 NS
6 (1%) 0.2 NS
4 (0.7%) 0.8 NS
5 (0.9%) 0.02 BMS vs. SES  0.02
BMS vs. PES  NS
SES vs. PES  NS
16 (2.8%) 0.9 NS
ed as early ST, categorized into acute ST (within 24 h) and subacute ST
ent thrombosis occurring1 year after the index procedure is definedto Dif
n  5
(7.5%)
(16.0%
(8.5%)
(11.6%
(21.2%
(9.6%)
(9.0%)
(12.5%
(3.5%)
(18.4%
(29.9%
(11.5%(
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1056hat the beneficial effect in reducing neointimal hyperplasia
ccurs in the first year, but most importantly the effect is
ustained at 6 years.
The 5-year results of the RAVEL (RAndomized study
ith the sirolimus-eluting VELocity balloon-expandable
tent4) clinical trial, which compared the SES with the
MS in patients with single de novo coronary lesions,
howed that target-lesion revascularization and MACE
ates were lower in SES patients compared with BMS
atients (10.3% vs. 26%, p  0.001; 25.8% vs. 35.2%, p 
.03, respectively) (3). These results were reproduced in the
-year clinical outcome results of the SIRIUS (Sirolimus-
luting Stent in De-Novo Native Coronary Lesions) trial
SES  9.4% vs. BMS  24.4%, p  0.001; SES  20.3%
s. BMS  33.5%, p  0.001, respectively) and the
AXUS (TAXUS IV-SR: Treatment of De Novo Coro-
Figure 2. Kaplan-Meier Curves According to Stent Type for the End Points
Adverse cardiac events with the associated log-rank test of patients treated wi
revascularization curve; (C) mortality curve; and (D) mortality/myocardial infarcary Disease Using a Single Paclitaxel-Eluting Stent) trial sPES  16.9% vs. BMS  27.4%, p  0.001; PES 
4.0% vs. BMS  32.8%, p  0.001) (5,29). The findings
f these clinical trials are mostly in line with the results
ound in our registries, in which we have used patient-
rientated MACE (death, any MI, any revascularization)
nstead of device-orientated MACE (cardiac death, target-
essel related MI, and target-lesion revascularization).
Although there were more patients with very-late stent
hrombosis in the SES and PES groups, it did not influence
he safety outcome of either stent. In spite of controversial
ndings of several large (multicenter) registries and clinical
rials concerning the possibility of an increased risk of
efinite very-late stent thrombosis with SES and PES
mplantation compared with BMS implantation, DES im-
lantation has never been associated with higher mortality
ates (30–32). Even though some factors causing very-late
S, SES, and PES: (A) major adverse cardiac event curve; (B) target vessel
MI) curve. Abbreviations as in Figure 1.th BMtent thrombosis are patient (behavior)-related, the higher
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1057ccurrence of late stent malapposition in SES and PES
atients compared with BMS is a stent type-related factor
ontributing to higher stent thrombosis rates (33). Previ-
usly published larger studies showed higher late stent
hrombosis rates in the PES population than in the SES
opulation (34,35). However, the main factor causing this
ifference in stent thrombosis rates between the different
tents remains undetermined, because of considerable dif-
erences in stent design (closed-cell design of the SES, and
he different strut thicknesses of the first- [132 m] and
econd-generation [97 m] PES), dissimilar stent rigidity,
nd inability to compare anti-restenotic mechanisms of the
rug and drug-release patterns of the stent platforms used
36,37).
Although “real-world” registries are the best way to
imic the complex clinical situation of most patients,
everal shortcomings need to be addressed and acknowl-
dged. Because the described cohorts are single-center,
onrandomized, and purely observational, they have differ-
nt complexity levels. During the inclusion years, increas-
ngly more diseased patients and more complex lesions were
eing treated with PCI. Although this has been corrected
or in statistical analysis, it is debatable whether this was
ufficient. Because the BMS population consisted of the
east complex patients and it had higher TVR rates and
ACE rates than SES and PES, the BMS has proven to be
nferior. It is noteworthy that nearly 20% of the SES
atients and 40% of the PES patients had a planned
ngiographic follow-up at 6 months. This is a possible
xplanation for the sudden rise of TVR rates at 6-month
ollow-up in the DES groups, in which oculostenotic-
Figure 3. Kaplan-Meier Curves According to Stent Type for
Stent Thrombosis
Abbreviations as in Figures 1 and 2.riven TVR might have occurred that had a negativenfluence on the end point, which actually strengthens our
urrent findings showing that DES have a better clinical
afety and efficacy compared with BMS. Third, some
ardiac events could have been missed, because of data
ollection relied on the ability of the patient to remember
vents of the past year. However, we have no reason to
elieve that this was not identically distributed between the
tent cohorts. Finally, the sample size of this study led to
nadequate statistical power for detecting differences for
tent thrombosis in the 3 cohorts.
The 6-year follow-up of the RESEARCH and
-SEARCH registries shows that SES and PES have a
eneficial effect on safety and efficacy outcome compared with
MS, in terms of decreased TVR procedures and, to a lesser
xtent, MACE when used in unselected de novo patients.
lthough the occurrence of more very late stent thrombosis in
ES and PES patients remains a safety concern, this did not
nfluence the safety end points all-cause mortality and the
omposite end point all-cause mortality/MI, which were
qually distributed. The safety and efficacy outcomes for SES
nd PES were similar for all end points.
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